Viewing Gene With Clinical Trials Data

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Report Bug Request Feature
Gene Data From HGNC: https://www.genenames.org/download/statistics-and-files/
Symbol: IL5
Name: interleukin 5
Location: 05q31.1
Locus Group: protein-coding gene
Gene Type: Protein Coding
Locus Type: gene with protein product
ID+ Clinical Trials CompTox DrugMatrix Conditions Design Enrollment Locations Outcomes
Clinical Trials Data: https://classic.clinicaltrials.gov/api/gui/ref/download_all

Clinical Studies

NCT Number Status Brief Title View
NCT00017862 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome View
NCT05901207 Diagnostic and Prognostic Biomarkers for IgG4-related Disease View
NCT04181190 Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients View
NCT04084613 Mepolizumab Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece View
NCT03298061 Long-term Access Program LAP of Mepolizumab for Subjects Who Participated in Study MEA115921 View
NCT04538937 Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils View
NCT03610685 Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma View
NCT05365841 Role of Epithelial Barrier Integrity in Biologic Treatment Response of Severe Asthmatics WithOut Chronic Rhinosinusitis With Nasal Polyps CRSwNP View
NCT04617171 Benralizumab Initiated During Severe Asthma Attack View
NCT05708300 Biomarkers of Response to Mepolizumab Treatment in Patients With Nasal Polyps With or Without Bronchial Asthma View
NCT01113489 Assessment of Oxidative Stress Markers in the Upper and Lower Airways of Atopic Children Treated With Nebulized Beclomethasone View
NCT01111305 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis View
NCT04412044 Effect of Anti-interleukin 5 IL5 Therapy on Sputum Cells and Cytokines View
NCT01463644 Mepolizumab in Chronic Obstructive Pulmonary Diseases COPD With Eosinophilic Bronchitis View
NCT03470311 Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies View
NCT01830673 Regulatory T-cells After Subcutaneous Immunotherapy View
NCT04520165 Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma View
NCT04108962 Benralizumab in the Treatment of Patients With Severe Asthma With ABPA View
NCT04114396 Poor Response to Monoclonal Therapy in Asthma View
NCT04158050 Comparison of Biologicals in Treatment of Severe Asthma View
NCT04700852 Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis View
NCT06231498 The Epigenomic Signature of Eosinophilic Granulomatosis With Polyangiitis View
NCT06239441 Effectiveness of Anti-IL-5IL5R Inhibitors View
NCT05596656 IgE-mediated Allergies Among Type 1 Diabetes Mellitus Children Single Centre Observational Study View
NCT05895929 The Role of IL5 in Epithelial Cell Integrity View
NCT04256772 Anti-IL5 and Other Biotherapies in Cystic Fibrosis View
NCT02559791 Anti-Interleukin-5 IL5 Monoclonal Antibody MAb in Prednisone-dependent Eosinophilic Asthma View
NCT03221192 Qualitative Analysis of Subject Experience of Nasal Polyps View
NCT03324230 Exploring Asthma Exacerbations in Mepolizumab Treated Patients View